

**Freedom of Information Request: 0020**

University Hospitals Birmingham NHS Foundation Trust (UHB) completed a merger by acquisition of Heart of England NHS Foundation Trust (HEFT) on 1<sup>st</sup> April 2018. Due to historical differences in data collection/reporting across UHB and the former Heart of England NHS Foundation Trust this response has been provided by hospital site.

**Queen Elizabeth Hospital Birmingham**

**1 – Within your Health Trust how many patients are currently (within the past 3 months) being treated with the following treatments for Kidney Carcinoma (Renal Cell – RCC);**

**If you do not treat, where do you refer these patients ?**

We have provided the number of packs issued from our Pharmacy for the specified condition. Please see note 1 below.

| <b>Drug Name</b>               | <b>Packs Issued</b> |
|--------------------------------|---------------------|
| <b>Axinitib</b>                | <b>0</b>            |
| <b>Cabozantinib</b>            | <b>15</b>           |
| <b>Everolimus</b>              | <b>4</b>            |
| <b>Levantinib + Everolimus</b> | <b>0</b>            |
| <b>Nivolumab</b>               | <b>32</b>           |
| <b>Nivolumab + Ipilimumab</b>  | <b>0</b>            |
| <b>Pazopanib</b>               | <b>13</b>           |
| <b>Sunitinib</b>               | <b>0</b>            |
| <b>Temsirolimus</b>            | <b>0</b>            |
| <b>Tivozanib</b>               | <b>0</b>            |

**2 – Within your Health Trust how many patients are currently (within the past 3 months) being treated with the following treatments for Melanoma ?**

**If you do not treat, where do you refer these patients ?**

We have provided the number of packs issued from our Pharmacy for the specified condition. Please see note 1 below.

| <b>Drug Name</b>   | <b>Packs Issued</b> |
|--------------------|---------------------|
| <b>Bevacizumab</b> | <b>0</b>            |

|                              |         |
|------------------------------|---------|
| Dabrafenib                   | 240     |
| Dabrafenib + Trametinib      | 240 +94 |
| Dacarbazine (DTIC)           | 0       |
| Densoumab                    | 0       |
| Encorafenib with Binimetinib | 0       |
| Ipilumumb                    | 0       |
| Nivolumab                    | 31      |
| Nivolumab + Ipilumumb        | 0       |
| Pembrolizimab                | 0       |
| Tratmetinib                  | 0       |
| Vemurafenib                  | 0       |
| Vemurafenib + Cobimetinib    | 0       |

**2a – In the past 3 months, how many Melanoma patients were BRAF+?**

The Trust does hold this information, however, to provide it would require manually reviewing individual records. We estimate this would exceed 18 hours. We are therefore withholding this information under section 12 of the Freedom of Information Act.

**3 – Within your Health Trust how many patients are currently (within the past 3 months) being treated with the following treatments for Liver Cancer (Hepatic Cell – HCC);**

**If you do not treat, where do you refer these patients ?**

We have provided the number of packs issued from our Pharmacy for the specified condition. Please see note 1 below.

| Drug Name   | Packs Issued |
|-------------|--------------|
| Bevacizumab | 0            |
| Cisplatin   | 0            |
| Doxorubicin | 85           |
| Everolimus  | 0            |
| Lapatinib   | 0            |
| Lenvantinib | 0            |
| Sorafenib   | 12           |
| Sunitinib   | 0            |

**4 – Within your Health Trust how many patients are currently (within the past 3 months) being treated with the following treatments for Thyroid Cancer;**

**If you do not treat, where do you refer these patients ?**

We have provided the number of packs issued from our Pharmacy for the specified condition. Please see note 1 below.

| <b>Drug Name</b>    | <b>Packs Issued</b> |
|---------------------|---------------------|
| <b>Axitinib</b>     | <b>0</b>            |
| <b>Cabozantinib</b> | <b>0</b>            |
| <b>Lenvantinib</b>  | <b>0</b>            |
| <b>Pazopanib</b>    | <b>0</b>            |
| <b>Sorafenib</b>    | <b>0.5</b>          |
| <b>Sunitinib</b>    | <b>0</b>            |
| <b>Vandetanib</b>   | <b>0</b>            |

Note 1

The Trust does hold the information on the number of patients who received the specified treatments, however, the Trust does not prescribe by indication, and therefore to provide it would require manually reviewing individual records. We estimate this would exceed 18 hours. We are therefore withholding this information under section 12 of the Freedom of Information Act.

**Heartlands, Good Hope and Solihull Hospital**

**1 – Within your Health Trust how many patients are currently (within the past 3 months) being treated with the following treatments for Kidney Carcinoma (Renal Cell – RCC);**

**If you do not treat, where do you refer these patients ?**

Please see table below.

**2 – Within your Health Trust how many patients are currently (within the past 3 months) being treated with the following treatments for Melanoma ?**

**If you do not treat, where do you refer these patients ?**

Please see table below.

**2a – In the past 3 months, how many Melanoma patients were BRAF+ ?**

The Trust does hold this information, however, to provide it would require manually reviewing individual records. We estimate this would exceed 18 hours. We are therefore withholding this information under section 12 of the Freedom of Information Act.

**3 – Within your Health Trust how many patients are currently (within the past 3 months) being treated with the following treatments for Liver Cancer (Hepatic Cell – HCC);**

Please see table below.

**4 – Within your Health Trust how many patients are currently (within the past 3 months) being treated with the following treatments for Thyroid Cancer;**

**If you do not treat, where do you refer these patients ?**

Please see table below.

| <b>Drug</b>        | <b>Total patients</b> |
|--------------------|-----------------------|
| BEVACIZUMAB        | 7                     |
| CABOZANTINIB       | 5                     |
| CISPLATIN          | 77                    |
| DACARBAZINE        | 6                     |
| DENOSUMAB          | 405                   |
| DOXORUBICIN        | 30                    |
| EVEROLIMUS         | 4                     |
| IPILIMUMAB         | 1                     |
| LENVATINIB         | 3                     |
| NIVOLUMAB          | 8                     |
| PAZOPANIB          | 16                    |
| PEMBROLIZUMAB      | 17                    |
| SORAFENIB          | 2                     |
| SUNITINIB          | 7                     |
| TEMSIROLIMUS       | 1                     |
| <b>Grand Total</b> | <b>589</b>            |

The Trust does hold information on which condition these patients received treatment for, however the Trust does not prescribe by indication, therefore to provide it would require

manually reviewing individual records. We estimate this would exceed 18 hours. We are therefore withholding this information under section 12 of the Freedom of Information Act.